Home Compare JNJ vs LLY
Stock Comparison · Industry comparison · Drug Manufacturers - General

Johnson & Johnson vs Eli Lilly and Company: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Johnson & Johnson carrying a narrow edge on stability. Eli Lilly and Company still leads on growth and profitability, which keeps the comparison from looking entirely one-sided. The market setup is mixed, without a decisive signal in either direction. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Stability remains the main source of distance in the comparison.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. JNJ and LLY share the same industry classification.

For a similarity-based comparison, see how Johnson & Johnson and Eli Lilly and Company each position within their functional peer groups in AssetNext.

Peer-Relative Score
JNJ
Johnson & Johnson
73
Peer-Score
Signal qualityHigh
vs
LLY
Eli Lilly and Company
68
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: JNJ vs LLY Profitability 69 100 Stability 86 34 Valuation 69 44 Growth 69 88 JNJ LLY
Gap Ranking
#1 Stability +52
#2 Profitability +31
#3 Valuation +25
#4 Growth +19
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for JNJ and LLY Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer JNJLLY Relative valuation Structural strength

Johnson & Johnson and Eli Lilly and Company look relatively close on structure, but the price setup still leans toward Johnson & Johnson.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Stability
Johnson & Johnson ranks near the top of the group on stability; Eli Lilly and Company sits in the weaker half.
Profitability
On profitability, the edge still sits with Eli Lilly and Company, even though both profiles look solid.
Stability — Dominant Gap
JNJ
86
LLY
34
Gap+52in favour of JNJ

The clearest distance comes from a steadier profile over time.

What keeps the gap from being one-sided

Profitability still favours Eli Lilly and Company, with a 20.9-point operating margin advantage keeping the comparison from looking fully resolved.

What this means for the comparison

Stability points more clearly to Johnson & Johnson, but profitability and current pricing keep the broader result mixed.

Explore full peer positioning in AssetNext

Break down the JNJ vs LLY comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how JNJ and LLY each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.